The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Merck & Co. and Hanmi Pharmaceutical, a Seoul, South Korea-based pharmaceutical company, have formed an exclusive licensing agreement, in a deal worth up to $870 million, for the development, manufacture and commercialization of efinopegdutide,...
Johnson & Johnson’s (J&J) Janssen Pharmaceutical Companies have entered into a $1-billion agreement with the US government for the large-scale domestic manufacturing and delivery in the US of 100 million doses of Janssen’s SARS-CoV-2...
Sanofi and GlaxoSmithKline (GSK) has formed a $2.1-billion pact with the US government for the development and manufacturing of their COVID-19 vaccine candidate and are in advanced discussions with the European Commission for the supply of up to...
Elanco Animal Health, the former animal-health business of Eli Lilly and Company and now a stand-alone company, has closed its $6.89-billion acquisition of Bayer Animal Health.
The companies signed an agreement for the acquisition in August 2019....
The latest on manufacturing and potential treatments for COVID-19 with news from Pfizer, J&J, Gilead Sciences, Genentech, Inovio, and Glenmark.
US DOJ OKs Info-Sharing on mAb Mfg Among Pharma Companies The US Department of Justice (DOJ) says...
Sanofi and GlaxoSmithKline (GSK) have reached an agreement, subject to a final contract, with the UK government for the supply of up to 60 million doses of a COVID-19 vaccine developed by Sanofi in partnership with GSK. The vaccine is based on...
Sandoz, the generics and biosimilars arm of Novartis, has announced a joint investment with the Austrian federal government for antibiotics manufacturing in Europe.
Sandoz intends to invest more than EUR 150 million ($178 million) over the next...
The US government, through the US International Development Finance Corporation (DFC), has signed a letter of interest to provide a $765-million loan to Eastman Kodak Company to support the launch of Kodak Pharmaceuticals, a new arm of the company...
Moderna, a clinical-stage biopharmaceutical company developing messenger RNA (mRNA) therapeutics and vaccines, will receive an additional commitment of up to $472 million from the Biomedical Advanced Research and Development Authority (BARDA), part...
AstraZeneca has entered into a global development and commercialization agreement with Daiichi Sankyo, in a deal worth up to $6 billion, for DS-1062, Daiichi Sankyo’s antibody drug conjugate (ADC) for treating multiple tumor types.
DS-1062 is in...
The latest on manufacturing and potential treatments for COVID-19 with news from AstraZeneca, CanSino Biologics, CGT Catapult, Bharat Biotech, and Celltrion.
AstraZeneca Reports Promising Early-Trial Results of COVID-19 VaccineAstraZeneca reports...
GlaxoSmithKline (GSK) and CureVac, a Tubingen, Germany-based clinical-stage biopharmaceutical company developing a messenger ribonucleic acid (mRNA) therapeutics, have signed a strategic collaboration agreement, in a deal worth up to £866 million...
Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, have entered an agreement with the US Department of Health and Human Services and the Department of Defense, in a deal worth up to $1.95 billion, to provide up to 600 million doses...
A roundup of news from Switzerland (BI, Numab Therapeutics) and the US (Bayer, Elanco, Mylan, Merck & Co, Dewpoint Therapeutics, and Nephron Pharmaceuticals).
Switzerland
BI, Numab Therapeutics in Pact for Antibody Therapies for Cancer,...
Roche and Blueprint Medicines, a Cambridge, Massachusetts-based biopharmaceutical company, have signed a licensing and collaboration agreement, in a deal worth up to $1.7 billion, to develop and commercialize pralsetinib, an investigational oral...
